New hope for tough pancreatic cancers: trial tests Immune-Boosting drug combo
NCT ID NCT05688215
Summary
This study is testing whether adding two new drugs (zimberelimab and quemliclustat) to standard chemotherapy can help people with pancreatic cancer that is difficult or impossible to remove with surgery. The new drugs aim to boost the immune system's ability to fight the cancer. Researchers want to see if this combination is safe, helps shrink tumors enough for surgery, or slows the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonemoto,Lisa
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.